Patent application number | Description | Published |
20090048337 | Modulation of anxiety through blockade of anandamide hydrolysis - Fatty acid amide hydrolase inhibitors of the Formula: | 02-19-2009 |
20090082435 | Methods, Compositions, And Compounds For Modulation Of Monoacylglycerol Lipase, Pain, And Stress-Related Disorders - Methods, compositions, and compounds for inhibiting monoacyglycerol lipase, and for treating pain, for modulating stress-induced analgesia or for treating stress-induced disorders in mammals are provided. | 03-26-2009 |
20120010283 | MODULATION OF ANXIETY THROUGH BLOCKADE OF ANANDAMIDE HYDROLYSIS - Fatty acid amide hydrolase inhibitors of the Formula: | 01-12-2012 |
20130217764 | PERIPHERALLY RESTRICTED FAAH INHIBITORS - Peripherally restricted inhibitors of fatty acid amide hydrolase (FAAH) are provided. The compounds can suppress FAAH activity and increases anandamide levels outside the central nervous system (CNS). Despite their relative inability to access brain and spinal cord, the compounds attenuate behavioral responses indicative of persistent pain in rodent models of inflammation and peripheral nerve injury, and suppresses noxious stimulus-evoked neuronal activation in spinal cord regions implicated in nociceptive processing. CBi receptor blockade prevents these effects. Accordingly, the invention also provides methods, and pharmaceutical compositions for treating conditions in which the inhibition of peripheral FAAH would be of benefit. The compounds of the invention are according to the formula (I): in which R | 08-22-2013 |
20140094508 | COMPOSITIONS AND METHODS OF INHIBITING N-ACYLETHANOLAMINE-HYDROLYZING ACID AMIDASE - Compounds and pharmaceutical compositions are contemplated that inhibit N-acyl-ethanolamine-hydrolyzing acid amidase (NAAA) to so increase the concentration of the substrate of NAAA, palmitoylethanolamide (PEA). NAAA inhibition is contemplated to be effective to alleviate conditions associated with a reduced concentration of PEA. Among other uses, various NAAA inhibitors are especially contemplated as therapeutic agents in the treatment of inflammatory diseases. | 04-03-2014 |
Patent application number | Description | Published |
20080261885 | PROCESS FOR THE EXTRACTION, PURIFICATION AND ENZYMATIC MODIFICATION OF SOY 7S GLOBULIN ALPHA' SUBUNIT FOR USE AS HYPOCHOLESTEROLEMIZING AGENT - A process for the extraction, purification and enzymatic modification of β-conglycinin α′ subunit, wherein β-conglycinin is selectively extracted from ground, defatted soy, then precipitated by treatment with aqueous ethanol; the enriched fraction is then subjected to Metal Affinity Chromatography (MAC) in denaturant conditions to obtain the α′ subunit, which is treated with chymotrypsin, then subjected to a further MAC to recover the amino-terminal region of this polypeptide (MW 28,000 Da). | 10-23-2008 |
20110118182 | PROCESS FOR THE EXTRACTION, PURIFICATION AND ENZYMATIC MODIFICATION OF SOY 7S GLOBULIN ALPHA' SUBUNIT FOR USE AS HYPOCHOLESTEROLEMIZING AGENT - A purified amino-terminal polypeptide fragment of the soy β-conglycinin α′ subunit is prepared by selective extraction of defatted soy with an aqueous solution of sodium bisulfite, precipitation with ethanol, and Metal Affinity Chromatography (MAC) under denaturing conditions to obtain the α′ subunit. The α′ subunit is then enzymatically treated with chymotrypsin and subjected to further MAC to recover the amino-terminal fragment of the polypeptide (MW 28,000 Da). | 05-19-2011 |
20120172316 | CLONING, YEAST EXPRESSION, PURIFICATION AND BIOLOGICAL ACTIVITY OF THE EXTENSION REGION OF THE SOYBEAN 7S GLOBULIN ALFA' SUBUNIT INVOLVED IN HEP G2 CELL CHOLESTEROL HOMEOSTASIS - A truncated form of α′ chain (eα′), the soybean 7S globulin, active in controlling the cholesterol and triglyceride homeostasis in in vitro and in vivo models, was cloned and expressed in the yeast | 07-05-2012 |